J&J Cypher warning letter update
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis expects a "final resolution" of several Cypher drug-eluting stent-related GMP violations by the first half of 2005 at the latest, VP-Investor Relations Helen Short said during a Sept. 13 session of the Bear Stearns Healthcare Conference in New York (1"The Gray Sheet" April 12, 2004, p. 3). Cited in an FDA warning letter April 1, the violations included a lack of timely failure analysis reports on thrombosis complaints. J&J is in discussions with the agency about the timing of follow-up inspections at facilities cited in the letter, Short noted, adding that they center around whether FDA would expect 100% completion of corrective measures by the time inspectors arrive or just a demonstration that it is "making progress and would complete things in a reasonable time"...
You may also be interested in...
Increased Cypher Shipments Unhindered By Cordis Warning Letter – J&J Exec
Johnson & Johnson will ramp up inventory of the Cypher sirolimus-eluting stent to fulfill existing back-orders over the next several weeks
Cypher Warning Letter Cites Systemic GMP Problems At Multiple Facilities
Johnson & Johnson/Cordis' inability to provide timely failure analysis reports of Cypher-related thrombosis complaints is one of several GMP violations cited in an April 1 FDA 1warning letter
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.